Viridian Therapeutics reported positive phase 1 results for VRDN-008, including 74% peak IgG reduction and an extended half-life of 15–18 days. It plans a pivotal MG trial in mid-2027, pending regulatory feedback.
VRDN · Viridian Therapeutics, Inc.DE
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 48%
- Last earnings
- Nov 4, 2026
- Latest filing
- 10-Q · Nov 4
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Viridian’s LUMVOA launch generated $24.7 million in net product revenue, with more than 100 patients starting treatment. Broad payer coverage is targeted six to nine months from launch, and cash, cash equivalents and marketable securities totaled just over $955 million.
Viridian Therapeutics launched Lumvoa in the United States after FDA approval in June 2026, generating $24.7 million in product revenue during the third quarter of 2026. More than 100 patients had started therapy as of September 30, 2026.
Viridian Therapeutics, Inc. reported $24.7 million in Lumvoa net product revenue for the third quarter ended September 30, 2026, and $955.2 million in cash as of September 30, 2026. Elegrobart’s BLA submission remains on track for the first quarter of 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 4, 2026TL;DR. Lumvoa exceeded launch expectations with $24.7 million of net product revenue and more than 100 patients on therapy; payer policies covered 30% of covered lives, and a permanent J-code was assigned effective January 1, 2027. Elegrobart’s BLA and VRDN-292 and VRDN-008 milestones remain on track, while SG&A and net loss increased and launch durability remains uncertain.
- + Patient and physician enthusiasm was translating into meaningful Lumvoa launch momentum.
- + Lumvoa policies covered 30% of covered lives at September-end, with broad coverage targeted within six to nine months of launch.
- + Existing cash and anticipated future commercial revenues were expected to fund current business plans through profitability.
- − The durability of Lumvoa’s early launch remains unproven and must be observed over subsequent quarters.
- − Payer policy adoption takes time, with differing payer decision timelines.
- − The J-code transition can create cash-flow issues for infusion centers, and Viridian provided relief through extended payment terms reflected in accounts receivable.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Shares of common stock outstanding on an as-converted basis | 125,636,093 | As of September 30, 2026 | — |
| Core prescribing physicians | 2,000 | as of July 31, 2026 | — |
| Core prescribing physicians engaged | 95% | as of July 31, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VRDN
this stock
Viridian Therapeutics, Inc.DE
|
$3.40B | -3.7% | -12.0% | — | 15.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 9, 2026
- This year
- 22
Viridian Therapeutics reported positive phase 1 results for VRDN-008, including 74% peak IgG reduction and an extended half-life of 15–18 days. It plans a pivotal MG trial in mid-2027, pending regulatory feedback.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VRDN | -3.0% | +33.9% | +88.8% | +21.4% | -3.7% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +5.6% | +43.2% | +98.0% | +30.2% | -4.9% |